BOSTON, March 9, 2021 – Volastra Therapeutics and Dewpoint Therapeutics today announced a research and development partnership to discover novel modulators of biomolecular condensates […]

BOSTON, February 16, 2021 – Dewpoint Therapeutics, the biomolecular condensates company, today announced that it has appointed Regina Barzilay, Ph.D., to its […]

BOSTON, February 11, 2021 — Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Joel Sendek as Chief Financial Officer […]

BOSTON, January 6, 2021 —  Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) […]

BOSTON, December 9, 2020 — Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Kara Carter, Ph.D., as Senior […]

Dewpoint Therapeutics congratulates Scientific founder Anthony Hyman on receiving the 2021 HFSP Nakasone Award from The Human Frontier Science Program […]

BOSTON, October 13, 2020 —  Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Ameet Nathwani, M.D., as Chief Executive […]

BOSTON, September 29, 2020 – Dewpoint Therapeutics, the biomolecular condensates company, today announced it has raised $77 million in a Series B […]

We are proud to have been featured by Business Insider as one of 21 start-ups considered by top biotech venture […]

BOSTON, July 13, 2020  —  Dewpoint Therapeutics, the biomolecular condensates company, announced today that it has forged an exclusive collaboration agreement with Merck, known as […]